Download PDF
Digestive Disease Interventions 2020; 04(04): 345-350
DOI: 10.1055/s-0040-1718902
Review Article

Adoptive Cell Therapy for Gastrointestinal Cancers

Ryan J. Slovak
1   Section of Interventional Radiology, Yale School of Medicine, New Haven, Connecticut
,
Hyun S. Kim 
1   Section of Interventional Radiology, Yale School of Medicine, New Haven, Connecticut
2   Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut
3   Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut
› Author Affiliations Funding H.S.K. is supported by the United States Department of Defense (CA160741). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
› Further Information
Also available at
    Permissions and Reprints

Abstract

The reinfusion of autologous or allogeneic immune cells that have been educated and/or engineered ex vivo to respond to tumor-specific antigens is termed “adoptive cell therapy.” While adoptive cell therapy has made tremendous strides in the treatment of hematologic malignancies, its utilization for solid tumors has lagged somewhat behind. The purpose of this article is to concisely review the clinical research that has been done to investigate adoptive cell therapy as a treatment for gastrointestinal malignancies.

Keywords

adoptive cell therapy - cytokine-induced killer cells - CAR-T - TCR engineering - immunotherapy


Publication History

Received: 15 July 2020

Accepted: 18 August 2020

Article published online:
19 November 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Rohaan MW, Wilgenhof S, Haanen JBAG. Adoptive cellular therapies: the current landscape. Virchows Arch 2019; 474 (04) 449-461
    CrossrefPubMedGoogle Scholar
  • 2 Fan J, Shang D, Han B, Song J, Chen H, Yang JM. Adoptive cell transfer: Is it a promising immunotherapy for colorectal cancer?. Theranostics 2018; 8 (20) 5784-5800
    CrossrefPubMedGoogle Scholar
  • 3 Met Ö, Jensen KM, Chamberlain CA, Donia M, Svane IM. Principles of adoptive T cell therapy in cancer. Semin Immunopathol 2019; 41 (01) 49-58
    CrossrefPubMedGoogle Scholar
  • 4 Mata-Molanes JJ, Sureda González M, Valenzuela Jiménez B, Martínez Navarro EM, Brugarolas Masllorens A. Cancer immunotherapy with cytokine-induced killer cells. Target Oncol 2017; 12 (03) 289-299
    CrossrefPubMedGoogle Scholar
  • 5 Ping Y, Liu C, Zhang Y. T-cell receptor-engineered T cells for cancer treatment: current status and future directions. Protein Cell 2018; 9 (03) 254-266
    CrossrefPubMedGoogle Scholar
  • 6 Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol 2019; 94 (S1): S3-S9
    CrossrefPubMedGoogle Scholar
  • 7 Schmitt TM, Aggen DH, Stromnes IM. et al. Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood 2013; 122 (03) 348-356
    CrossrefPubMedGoogle Scholar
  • 8 Yang JC. Toxicities associated with adoptive T-cell transfer for cancer. Cancer J 2015; 21 (06) 506-509
    CrossrefPubMedGoogle Scholar
  • 9 Gardini A, Ercolani G, Riccobon A. et al. Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis. J Surg Oncol 2004; 87 (01) 46-52
    CrossrefPubMedGoogle Scholar
  • 10 Tran E, Robbins PF, Lu YC. et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med 2016; 375 (23) 2255-2262
    CrossrefPubMedGoogle Scholar
  • 11 Kim JA, Bresler HS, Martin Jr EW, Aldrich W, Heffelfinger M, Triozzi PL. Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody. Cancer 1999; 86 (01) 22-30
    CrossrefPubMedGoogle Scholar
  • 12 Satoh K, Kan N, Okino T. et al. The therapeutic effect of OK-432-combined adoptive immunotherapy against liver metastases from gastric or colorectal cancers. Biotherapy 1993; 6 (01) 41-49
    CrossrefPubMedGoogle Scholar
  • 13 Karlsson M, Marits P, Dahl K. et al. Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer. Ann Surg Oncol 2010; 17 (07) 1747-1757
    CrossrefPubMedGoogle Scholar
  • 14 Zhen YH, Liu XH, Yang Y. et al. Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer. Cancer Immunol Immunother 2015; 64 (09) 1083-1093
    CrossrefPubMedGoogle Scholar
  • 15 Schmidt-Wolf IG, Finke S, Trojaneck B. et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 1999; 81 (06) 1009-1016
    CrossrefPubMedGoogle Scholar
  • 16 Zhang J, Zhu L, Zhang Q. et al. Effects of cytokine-induced killer cell treatment in colorectal cancer patients: a retrospective study. Biomed Pharmacother 2014; 68 (06) 715-720
    CrossrefPubMedGoogle Scholar
  • 17 Lin T, Song C, Chuo DY, Zhang H, Zhao J. Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study. Tumour Biol 2016; 37 (04) 4367-4372
    CrossrefPubMedGoogle Scholar
  • 18 Sakamoto N, Ishikawa T, Kokura S. et al. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J Transl Med 2015; 13: 277
    CrossrefPubMedGoogle Scholar
  • 19 Ishikawa T, Okayama T, Sakamoto N. et al. Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer. Int J Cancer 2018; 142 (12) 2599-2609
    CrossrefPubMedGoogle Scholar
  • 20 Parkhurst MR, Yang JC, Langan RC. et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011; 19 (03) 620-626
    CrossrefPubMedGoogle Scholar
  • 21 Zhang C, Wang Z, Yang Z. et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers. Mol Ther 2017; 25 (05) 1248-1258
    CrossrefPubMedGoogle Scholar
  • 22 Katz SC, Burga RA, McCormack E. et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin Cancer Res 2015; 21 (14) 3149-3159
    CrossrefPubMedGoogle Scholar
  • 23 Kono K, Ichihara F, Iizuka H, Sekikawa T, Matsumoto Y. Differences in the recognition of tumor-specific CD8+ T cells derived from solid tumor, metastatic lymph nodes and ascites in patients with gastric cancer. Int J Cancer 1997; 71 (06) 978-981
    CrossrefPubMedGoogle Scholar
  • 24 Xu X, Xu L, Ding S. et al. Treatment of 23 patients with advanced gastric cancer by intravenously transfer of autologous tumor-infiltrating lymphocytes combined with rIL-2. Chin Med Sci J 1995; 10 (03) 185-187
    PubMedGoogle Scholar
  • 25 Zhang GQ, Zhao H, Wu JY. et al. Prolonged overall survival in gastric cancer patients after adoptive immunotherapy. World J Gastroenterol 2015; 21 (09) 2777-2785
    CrossrefPubMedGoogle Scholar
  • 26 Jiang JT, Shen YP, Wu CP. et al. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol 2010; 16 (48) 6155-6162
    CrossrefPubMedGoogle Scholar
  • 27 Shi L, Zhou Q, Wu J. et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother 2012; 61 (12) 2251-2259
    CrossrefPubMedGoogle Scholar
  • 28 Zhao H, Fan Y, Li H. et al. Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma: a retrospective study of 165 patients. Cancer Biother Radiopharm 2013; 28 (04) 303-309
    CrossrefPubMedGoogle Scholar
  • 29 Liu K, Song G, Hu X. et al. A positive role of cytokine-induced killer cell therapy on gastric cancer therapy in a Chinese population: a systematic meta-analysis. Med Sci Monit 2015; 21: 3363-3370
    CrossrefPubMedGoogle Scholar
  • 30 Mu Y, Zhou CH, Chen SF. et al. Effectiveness and safety of chemotherapy combined with cytokine-induced killer cell/dendritic cell-cytokine-induced killer cell therapy for treatment of gastric cancer in China: a systematic review and meta-analysis. Cytotherapy 2016; 18 (09) 1162-1177
    CrossrefPubMedGoogle Scholar
  • 31 Toh U, Yamana H, Sueyoshi S. et al. Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res 2000; 6 (12) 4663-4673
    PubMedGoogle Scholar
  • 32 Kageyama S, Ikeda H, Miyahara Y. et al. Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer. Clin Cancer Res 2015; 21 (10) 2268-2277
    CrossrefPubMedGoogle Scholar
  • 33 Higuchi R, Yamamoto M, Hatori T, Shimizu K, Imai K, Takasaki K. Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery: report of a case. Surg Today 2006; 36 (06) 559-562
    CrossrefPubMedGoogle Scholar
  • 34 Tran E, Turcotte S, Gros A. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014; 344 (6184): 641-645
    CrossrefPubMedGoogle Scholar
  • 35 Shimizu K, Kotera Y, Aruga A, Takeshita N, Takasaki K, Yamamoto M. Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2012; 19 (02) 171-178
    CrossrefPubMedGoogle Scholar
  • 36 Liu H, Song J, Yang Z, Zhang X. Effects of cytokine-induced killer cell treatment combined with FOLFOX4 on the recurrence and survival rates for gastric cancer following surgery. Exp Ther Med 2013; 6 (04) 953-956
    CrossrefPubMedGoogle Scholar
  • 37 Chen Y, Guo ZQ, Shi CM, Zhou ZF, Ye YB, Chen Q. Efficacy of adjuvant chemotherapy combined with immunotherapy with cytokine-induced killer cells for gastric cancer after d2 gastrectomy. Int J Clin Exp Med 2015; 8 (05) 7728-7736
    PubMedGoogle Scholar